Dragonfly announces that Dr. Ann Cheung will become its Head of Biology, leading critical development of the company's novel Natural Killer cell-based immunotherapies.
CAMBRIDGE, Mass., May 16, 2017 /CNW/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Dr. Ann Cheung will become its Head of Biology, directing key immuno-oncology functions for the development of its novel Natural Killer ("NK") cell-based therapies.
"Ann is an outstanding scientist," said Dragonfly co-founder and head of the Koch Institute for Integrative Cancer Research at MIT, Dr. Tyler Jacks. "After working with her for six years in MIT labs earlier in her career, I know that she will bring immense creativity, innovation, experience and drive to her important role as Dragonfly's Head of Biology.
As Dragonfly's Head of Biology, Dr. Cheung manages all immune-oncology functions for the development of the company's proprietary NK cell engagers, directing research into NK cell biology and mechanism of action. She works closely with the Head of Biologics, Dr. Asya Grinberg.
At the Jacks lab, Ann studied the interface of between lung tumors and anti-cancer T cells, and initiated the group's forays into cancer immunology. Ann's postdoctoral work was at Caltech, and included a collaboration with Drs. Antoni Ribas and Nobel Laureate David Baltimore to assess T cell multi-functionality in a clinical trial using engineered T cells for immunotherapy in advanced melanoma patients. Ann received her undergraduate degree from Brown University with a concentration in Biochemistry and Molecular Biology, and received her Ph-D from the MIT Department of Biology.
Dragonfly Therapeutics harnesses its novel TriNKET technology to develop drugs that leverage the power of the innate immune system to provide breakthrough cancer treatments for patients.
SOURCE Dragonfly Therapeutics, Inc.